Literature DB >> 12582450

Therapeutic approaches to the treatment of Alzheimer's disease.

Kiyofumi Yamada1, Nabeshima Toshitaka.   

Abstract

Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-b immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease. Copyright 2002 Prous Science

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12582450     DOI: 10.1358/dot.2002.38.9.696538

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  3 in total

1.  Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.

Authors:  Oludotun O Adegoke; Fangfang Qiao; Yanying Liu; Kirsty Longley; Shelley Feng; Hongmin Wang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnestic mild cognitive impairment.

Authors:  Sabrina K Segal; Carl W Cotman; Lawrence F Cahill
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  A novel rhamnoside derivative PL402 up-regulates matrix metalloproteinase 3/9 to promote Aβ degradation and alleviates Alzheimer's-like pathology.

Authors:  Tingting Hu; Yue Zhou; Jing Lu; Peng Xia; Yue Chen; Xin Cao; Gang Pei
Journal:  Aging (Albany NY)       Date:  2020-01-05       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.